In this episode, recorded on-site at the ASGCT 2026 Annual Meeting, Molecular Therapy Advances Associate Editor-in-Chief Dr. Dan Stone speaks with Dr. Dan DuBreuil of Sanofi. They break down the science behind a recent paper detailing the development of a secretable frataxin, highlighting its potential to improve treatment efficacy for Friedreich’s ataxia.
Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au
Podden och tillhörande omslagsbild på den här sidan tillhör
American Society of Gene & Cell Therapy. Innehållet i podden är skapat av American Society of Gene & Cell Therapy och inte av,
eller tillsammans med, Poddtoppen.
